Scios Natrecor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA Cardiovascular & Renal Drugs Advisory Committee unanimously recommends on May 25 that nesiritide be approved for treatment of acute decompensated congestive heart failure. The group, however, was divided on the appropriate indication. Five members voted that the indication be limited to short-term treatment of acute decompensated heart failure, while five recommended that it also mention lowering of pulmonary capillary wedge pressure and improvement of symptoms. The committee suggested that Scios' physician education program emphasize Natrecor's potential for symptomatic hypotension. Scios anticipates a mid-July approval and a mid-August launch
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.